Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05754125
Other study ID # DiEx
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 21, 2023
Est. completion date January 30, 2024

Study information

Verified date November 2023
Source University of Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study seeks to investigate the anabolic potential of a dileucine-enriched essential amino acid (EAA) formulation compared with a branched chain amino acid (BCAA) alternative and a collagen beverage on muscle protein anabolism and catabolism following a bout of resistance exercise training. To do this, investigators will employ a novel 'breath test' method developed in our laboratory as well as blood and urine sampling. The results of this study will allow us to better understand the anabolic potential of dileucine which could have implications for people engaging in regular resistance training (such as athletes) as well as people that need to preserve muscle mass (older people who are susceptible to anabolic resistance and sarcopenia, or muscle wasting).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 12
Est. completion date January 30, 2024
Est. primary completion date July 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Trained individuals currently performing structured exercise (e.g., running, weightlifting, team-sport activity) at least 2 days per week for the previous 3 months Exclusion Criteria: - Inability to perform physical activity as determined by the PAR-Q - Inability to adhere to protocol guidelines (e.g., alcohol, habitual diet) - Regular tobacco use - Illicit drug use (e.g., growth hormone, testosterone, etc.) - Diagnosed medical condition under the care of a physician (e.g. type 2 diabetes) - Inability to abstain from supplements (e.g. protein, creatine, HMB, BCAA, phosphatidic acid, etc.) at least three weeks before the trial - Individuals on any medications known to affect protein metabolism (e.g., corticosteroids, non-steroidal anti-inflammatories, or prescription-strength acne medications) - Participants that are amenorrheic (females only) - On medications that may interfere with protein metabolism (e.g. anti-inflammatory drugs, hormone therapy) - Regular tobacco use (e.g. daily use of oral or inhaled tobacco) - Illicit drug use (e.g. growth hormone, testosterone, etc.) - Inability to comply with the study protocol as judged by the investigators

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Di-Leucine Supplement
Participants will consume a amino acid supplement containing Di-Leucine following resistance exercise and their whole body anabolism will be determined over the subsequent 6 hours
BCAA Supplement
Participants will consume a amino acid supplement containing branched chain amino acids (BCAA) following resistance exercise and their whole body anabolism will be determined over the subsequent hours
Collagen Supplement
Participants will consume a amino acid supplement containing Collagen protein following resistance exercise and their whole body anabolism will be determined over the subsequent hours

Locations

Country Name City State
Canada Goldring Centre for High Performance Sport at the University of Toronto Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
University of Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Whole-Body Protein Synthesis Investigators will measure the enrichment of [13CO2] in the breath by isotope ratio mass spectrometry (IRMS) in atom percent excess (APE). The measurement of carbon dioxide production (VCO2) and stable isotope tracer enrichment in the breath allows for the assessment of the rate at which amino acids are used for energy (i.e., oxidized), rather than for protein synthesis (i.e., retained in the body) by calculating the fraction of expired CO2 that contains 13C. Leucine retention (umol/kg) will then be calculated from the difference between the known amount of leucine provided (ingested) and leucine oxidation (as determined from 13CO2 breath enrichment). 6 hours
Secondary Urinary Measures (Muscle Protein Breakdown) Investigators will measure urinary 3-methylhistidine (3MH) as an indirect marker of muscle protein breakdown over the course of the trial (6 hours) through pooled urine collection vs baseline urine. 6 hours
Secondary Murine Cell-Based Experiments (ex-vivo experiments) -hypertrophy Investigators will use human serum obtained from fasted and fed timepoints (15, 30, 45 and 60 minutes following beverage consumption) to condition cell culture media (20% volume). To determine the effects of using fasted and/or fed 'human-conditioned' culture media on cell growth, myotube diameter (hypertrophy) will be measured via microscopy following short term (4 hours) and long-term (24 hour) incubation in the human conditioned culture media. 60 minutes
Secondary Murine Cell-Based Experiments (ex-vivo experiments) - Protein Synthesis Investigators will use human serum obtained from fasted and fed timepoints (15, 30, 45 and 60 minutes following beverage consumption) to condition cell culture media (20% volume). To determine the effects of using fasted and/or fed 'human-conditioned' culture media on cell protein synthesis, puromycin incorporation (measure of protein synthesis) will be measured via western blot. 60 minutes
Secondary Murine Cell-Based Experiments (ex-vivo experiments) - mTORC1 Signalling Investigators will use human serum obtained from fasted and fed timepoints (15, 30, 45 and 60 minutes following beverage consumption) to condition cell culture media (20% volume). To determine the effects of using fasted and/or fed 'human-conditioned' culture media on cell anabolic signalling mTORC1 signalling will be measured via western blot. 60 minutes
See also
  Status Clinical Trial Phase
Completed NCT05336708 - The Effect of Acupressure on Fatigue N/A
Recruiting NCT06054620 - The Effect of Exercise and Presleep Nutrition on Muscle Connective Tissue Remodelling N/A
Recruiting NCT05060484 - A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years Phase 2
Active, not recruiting NCT05554653 - Influence of Leucine Enriched Amino Acids on Myofibrillar and Collagen Protein Synthesis N/A
Completed NCT03756935 - Early Detection of Intra Operative Hypotension (IOH) During the Induction of General Anaesthesia
Recruiting NCT05145712 - Quantitative Bowel Readiness Assessment System in Predicting the Missed Detection Rate of Adenomas N/A
Not yet recruiting NCT06468046 - Mama Empoderada: Adapting a Novel Mental Health Prevention Intervention for Migrant Mothers With Young Children N/A
Completed NCT03853226 - Rational for the Use of Velocity-Pressure Loop in the Operating Room
Recruiting NCT03921164 - Non Invasive Use of Pressure-Volume Loop in the Operating Room
Completed NCT03876379 - Brain Power Spectral Density Under Propofol
Recruiting NCT02778724 - France PCI Registry : National Observatory of Interventional Cardiology
Terminated NCT03585855 - Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Antibody Mediated Kidney Graft Rejection (ABMR) N/A
Completed NCT03769142 - Cerebral Perfusion During Induction of General Anesthesia